Back to Search Results
Image Place holder

Don Klippenstein, MD

Vice Chair, Department of Diagnostic Imaging and Interventional Radiology

 
Specialty: Radiology
Sub Specialty: Diagnostic Radiology
Program: Diagnostic Imaging and Interventional Radiology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Dr. Klippenstein works and specializes in Diagnostic Radiology including tumor imaging in the thorax, abdomen and pelvis. His research interests include imaging in tumor response assessment, early lung cancer detection with low-dose CT, and ultrasound guided procedures. Dr. Klippenstein graduated from the University of Minnesota Medical School at Minneapolis. 


Education & Training

Fellowship:

  • University Hospitals, University of Michigan - US/MR/CT Body Imaging

Residency:

  • Brigham and Women's Hospital, Harvard Medical School - Diagnostic Radiology

Medical School:

  • University of Minnesota Medical School - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Wood DE, Kazerooni EA, Aberle D, Berman A, Brown LM, Eapen GA, Ettinger DS, Ferguson JS, Hou L, Kadaria D, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Mazzone P, Merritt RE, Midthun DE, Onaitis M, Pipavath S, Pratt C, Puri V, Raz D, Reddy C, Reid ME, Sandler KL, Sands J, Schabath MB, Studts JL, Tanoue L, Tong BC, Travis WD, Wei B, Westover K, Yang SC, McCullough B, Hughes M. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. J Natl Compr Canc Ne. 2022 Jul.20(7):754-764. Pubmedid: 35830884.
  • Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Apr.16(4):412-441. Pubmedid: 29632061. Pmcid: PMC6476336.
  • Arrington JA, Klippenstein DL, Gatenby RA. Innovations in Diagnostic Imaging and the Transformation of the Clinical Practice of Radiology in Collaborative, Multidisciplinary Cancer Care. Cancer Control. 2017 Apr.24(2):115-117. Pubmedid: 28441378.
  • Juárez Salcedo LM, Sandoval-Sus J, Zhang L, Klippenstein D, Chavez JC. Excellent outcome of hairy cell leukaemia with extensive mesenteric infiltration following cladribine therapy. Brit J Haematol. 2016 Sep.174(5):659. Pubmedid: 27391097.
  • Valderrabano P, Klippenstein DL, Tourtelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, McIver B. New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis. Thyroid. 2016 Aug.26(8):1093-1100. Pubmedid: 27267210. Pmcid: PMC7871990.
  • Wang H, Schabath MB, Liu Y, Berglund AE, Bloom GC, Kim J, Stringfield O, Eikman EA, Klippenstein DL, Heine JJ, Eschrich SA, Ye Z, Gillies RJ. Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. Clin Lung Cancer. 2015 Nov.16(6):e141-e163. Pubmedid: 26077095. Pmcid: PMC4609593.
  • Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2015 Jan.13(1):23-34. Pubmedid: 25583767.
  • Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010 Jan.116(1):84-92. Pubmedid: 19862816.
  • Gottlieb RH, Kumar P, Loud P, Klippenstein D, Raczyk C, Tan W, Lu J, Ramnath N. Semiquantitative visual approach to scoring lung cancer treatment response using computed tomography: a pilot study. J Comput Assist Tomo. 2009 Sep.33(5):743-747. Pubmedid: 19820504.
  • Patel AV, Bogner PN, Klippenstein D, Ramnath N. Malignant pleural mesothelioma after household exposure to asbestos. J Clin Oncol. 2008 Nov.26(33):5480-5483. Pubmedid: 18955439.
  • IELCAP, Klippenstein D. Computed tomographic screening for lung cancer: individualising the benefit of the screening. Eur Respir J. 2007 Nov.30(5):843-847. Pubmedid: 17652316.
  • Carter D, Vazquez M, Flieder DB, Brambilla E, Gazdar A, Noguchi M, Travis WD, Kramer A, Yip R, Yankelevitz DF, Henschke CI, Klippenstein D. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer. 2007 May.56(2):193-199. Pubmedid: 17239983.
  • Cheruvu B, Henning K, Mulligan J, Klippenstein D, Lawrence D, Gurtoo L, Gottlieb RH. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomo. 2007 Jul.31(4):493-498. Pubmedid: 17882021.
  • Klippenstein DL, Lamonica DM. Preoperative imaging for metastasectomy. Surg Oncol Clin N Am. 2007 Jul.16(3):471-92, vii. Pubmedid: 17606189.
  • NYELCAP, Klippenstein D. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology. 2007 Apr.243(1):239-249. Pubmedid: 17392256.
  • Loewen G, Natarajan N, Tan D, Nava E, Klippenstein D, Mahoney M, Cummings M, Reid M. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax. 2007 Apr.62(4):335-340. Pubmedid: 17101735. Pmcid: PMC2092474.
  • Tockman M, Henschke C, Yankelevitz D, Libby D, Pasmantier M, Smith J, Miettinen O, Klippenstein D. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006 Oct.355(17):1763-1771. Pubmedid: 17065637.
  • Henschke CI, Lee IJ, Wu N, Farooqi A, Khan A, Yankelevitz D, Altorki NK, Klippenstein D. CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiology. 2006 May.239(2):586-590. Pubmedid: 16641357.
  • Henschke CI, Yip R, Miettinen OS, Klippenstein D. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006 Jul.296(2):180-184. Pubmedid: 16835423.
  • Henschke CI, Yankelevitz DF, Miettinen OS, Klippenstein D. Computed tomographic screening for lung cancer: the relationship of disease stage to tumor size. Arch Intern Med. 2006 Feb.166(3):321-325. Pubmedid: 16476872.
  • Henschke CI, Klippenstein D. CT screening for lung cancer: update 2005. Surg Oncol Clin N Am. 2005 Oct.14(4):761-776. Pubmedid: 16226690.
  • Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005 Nov.106(10):3348-3352. Pubmedid: 16051743.
  • Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005 Feb.23(4):694-704. Pubmedid: 15681517.
  • Loewen G, Reid M, Tan D, Klippenstein D, Nava E, Natarajan R, Mahoney M. Bimodality lung cancer screening in high-risk patients: a preliminary report. Chest. 2004 May.125(5 Suppl):163S-164S. Pubmedid: 15136489.
  • Wilkinson NW, Loewen GM, Klippenstein DL, Litwin AM, Anderson TM. The evolution of lung cancer screening. J Surg Oncol. 2003 Dec.84(4):234-238. Pubmedid: 14756435.
  • Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002 Jun.20(12):2844-2850. Pubmedid: 12065561.
  • Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002 Feb.29(1 Suppl 2):36-40. Pubmedid: 11842387.
  • Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002 Feb.29(1S2):36-40. Pubmedid: 28140090.
  • Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm. 2002 Dec.17(6):689-697. Pubmedid: 12537673.
  • Bruce D, Loud PA, Klippenstein DL, Grossman ZD, Katz DS. Combined CT venography and pulmonary angiography: how much venous enhancement is routinely obtained?. Ajr Am J Roentgenol. 2001 May.176(5):1281-1285. Pubmedid: 11312195.
  • Loud PA, Katz DS, Bruce DA, Klippenstein DL, Grossman ZD. Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology. 2001 May.219(2):498-502. Pubmedid: 11323478.
  • Katz DS, Loud PA, Klippenstein DL, Shah RA, Grossman ZD. Extra-thoracic findings on the venous phase of combined computed tomographic venography and pulmonary angiography. Clin Radiol. 2000 Mar.55(3):177-181. Pubmedid: 10708608.
  • Federle MP, Chezmar JL, Rubin DL, Weinreb JC, Freeny PC, Semelka RC, Brown JJ, Borello JA, Lee JK, Mattrey R, Dachman AH, Saini S, Harmon B, Fenstermacher M, Pelsang RE, Harms SE, Mitchell DG, Halford HH, Anderson MW, Johnson CD, Francis IR, Bova JG, Kenney PJ, Klippenstein DL, Foster GS, Turner DA. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety). J Magn Reson Imaging. 2000 Jul.12(1):186-197. Pubmedid: 10931579.
  • Loud PA, Katz DS, Klippenstein DL, Shah RD, Grossman ZD. Combined CT venography and pulmonary angiography in suspected thromboembolic disease: diagnostic accuracy for deep venous evaluation. Ajr Am J Roentgenol. 2000 Jan.174(1):61-65. Pubmedid: 10628455.
  • Grillo-López AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, Klippenstein DL, Shen CD. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol. 2000 Apr.11(4):399-408. Pubmedid: 10847457.
  • Lamonica D, Grossman Z, Klippenstein D, Wang H, Vilani J, Nabi HA. A Comparative Study of 511 keV SPECT and PET Using Separate 370 MBq F-18-FDG Doses on Different Days. Clin Positron Imaging. 1999 Mar.2(2):81-91. Pubmedid: 14516544.
  • Stomper PC, Waddell BE, Edge SB, Klippenstein DL. Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma. Breast J. 1999 Jul.5(4):230-234. Pubmedid: 11348292.
  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr.17(4):1244. Pubmedid: 10561185.
  • Kahlenberg MS, Volpe C, Klippenstein DL, Penetrante RB, Petrelli NJ, Rodriguez-Bigas MA. Clinicopathologic effects of cryotherapy on hepatic vessels and bile ducts in a porcine model. Ann Surg Oncol. 1998 Dec.5(8):713-718. Pubmedid: 9869518.
  • Loud PA, Grossman ZD, Klippenstein DL, Ray CE. Combined CT venography and pulmonary angiography: a new diagnostic technique for suspected thromboembolic disease. Ajr Am J Roentgenol. 1998 Apr.170(4):951-954. Pubmedid: 9530042.
  • Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat. 1997 Aug.45(1):39-46. Pubmedid: 9285115.
  • Stomper PC, Winston JS, Herman S, Klippenstein DL, Blumenson LE. Cathepsin D and dynamic magnetic resonance imaging gadolinium enhancement in malignant and benign breast lesions. Clin Cancer Res. 1997 Apr.3(4):559-563. Pubmedid: 9815720.
  • Stomper PC, Herman S, Klippenstein DL, Winston JS, Budnick RM, Stewart CC. Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer. 1996 May.77(9):1844-1849. Pubmedid: 8646683.
  • Rodríguez-Bigas MA, Klippenstein D, Meropol NJ, Weber TK, Petrelli NJ. A pilot study of cryochemotherapy for hepatic metastases from colorectal cancer. Cryobiology. 1996 Dec.33(6):600-606. Pubmedid: 8975687.
  • Stomper PC, Herman S, Klippenstein DL, Winston JS, Edge SB, Arredondo MA, Mazurchuk RV, Blumenson LE. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology. 1995 Nov.197(2):387-395. Pubmedid: 7480682.
  • Klippenstein DL, Zerin JM, Hirschl RB, Donn SM. Splenic enlargement in neonates during ECMO. Radiology. 1994 Feb.190(2):411-412. Pubmedid: 8284390.
  • Green MA, Klippenstein DL, Tennison JR. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med. 1988 Sep.29(9):1549-1557. Pubmedid: 3261785.
  • Tyree B, Horigan EA, Klippenstein DL, Hassell JR. Heterogeneity of heparan sulfate proteoglycans synthesized by PYS-2 cells. Arch Biochem Biophys. 1984 Jun.231(2):328-335. Pubmedid: 6233937.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments